| October 26, 2005 |
| March 31, 2009 |
| December 2005 |
| May 2008 (final data collection date for primary outcome measure) |
| Efficacy of Two Different Treatment Regimens of Etanercept in Treating Skin Manifestations of Psoriasis Subjects With Psoriatic Arthritis. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ] |
| To compare the efficacy of the two different treatment regimens of etanercept in treating the skin manifestations of psoriasis subjects with psoriatic arthritis over 12 weeks. |
| Complete list of historical versions of study NCT00245960 on ClinicalTrials.gov Archive Site |
| Efficacy of Two Different Treatment Regimens of Etanercept in Treating Joint Disease. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ] |
| Compare the efficacy of two different treatment regimens of etanercept in treating the skin manifestations over 24 weeks and joint disease over 12 and 24 weeks. |
| |
| Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis |
| A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis. |
To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations. |
| |
| Phase IV |
| Interventional |
| Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Efficacy Study |
| Psoriatic Arthritis |
| Drug: etanercept |
| |
| |
| |
| Completed |
| 752 |
| May 2008 |
| May 2008 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- 18 years of age or older at time of consent
- Active Psoriatic Arthritis
- Clinically stable, plaque psoriasis involving more than 10% of the body surface area
Exclusion Criteria:
- Evidence of skin conditions other than psoriasis that would interfere with skin examinations.
- Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation
- Prior exposure to any TNF-inhibitor, including etanercept
|
| Both |
| 18 Years and older |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| Argentina, Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Saudi Arabia, Serbia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom |
| |
| NCT00245960 |
| Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth |
| 0881A5-401 |
| Wyeth |
|
| Principal Investigator: |
Trial Manager |
For Argentina, scheima@wyeth.com or rendop@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Belgium, trials-BEL@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Denmark, Finland, Sweden, MedInfoNord@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Germany, medinfoDEU@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Greece, decresg@wyeth.com |
|
| Principal Investigator: |
Trial Manger |
For Hungary, WPBUMED@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Australia, Korea, Taiwan, medinfo@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Mexico, gomezlj@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Netherlands, trials-NL@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Poland, WPWZMED@wyeth.com |
|
| Principal Investigator: |
Trial manager |
For Switzerland, med@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Turkey, Erisc@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For UK, ukmedinfo@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Austria, WPVIMED@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Portugal,Saudi Arabia, clintrialparticipation@wyeth.com |
|
| Study Director: |
Medical Monitor |
Wyeth |
|
| Principal Investigator: |
Trial Manager |
For France, infomedfrance@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Italy, descresg@wyeth.com |
|
| Principal Investigator: |
Trial Manager |
For Spain, infomed@wyeth.com |
|
|
| Wyeth |
| March 2009 |
